KalVista to Present EKTERLY Data at 2026 AAAAI Meeting
Event summary
- KalVista accepted three abstracts for presentation at the 2026 AAAAI Annual Meeting.
- Poster presentations scheduled for February 27 and March 1, 2026.
- Topics include response drivers, treatment patterns, and patient burden in HAE.
- EKTERLY (sebetralstat) is the first and only oral on-demand treatment for HAE.
- US regulatory filing planned for 2026 to expand use to children aged 2–11.
The big picture
KalVista's presentation at the 2026 AAAAI meeting underscores the growing importance of oral on-demand treatments for rare diseases like HAE. The strategic focus on expanding EKTERLY's approval to younger patients and broadening its global availability positions the company to capture a larger share of the HAE treatment market. The upcoming data could further solidify EKTERLY's role as a foundational therapy in HAE management.
What we're watching
- Regulatory Expansion
- Whether KalVista can successfully secure approval for EKTERLY in the pediatric population by 2026.
- Clinical Efficacy
- How the data from the KONFIDENT-S study will impact market perception of EKTERLY's effectiveness.
- Market Penetration
- The pace at which KalVista can expand EKTERLY's global reach beyond current approved markets.
Related topics